Industry7 min read
CagriSema vs Tirzepatide: REIMAGINE 4 Diabetes Data
Novo's amylin/GLP-1 combo matched tirzepatide on weight but missed on blood sugar in the 68-week REIMAGINE 4 head-to-head. What it means for buyers.
Peptide Industry News
Brand launches, primer pieces, broader coverage.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Industry News
Industry7 min read
Pfizer Kills Oral GLP-1 Peptide: What's Left in Pipeline
Pfizer axed its ex-Metsera oral GLP-1 peptide and a phase 2 GIPR antagonist. What survived the cut, and what it changes for research-peptide sourcing.
Industry7 min read
What Doctors Think About Peptides: New Survey Data
48% of physicians say patients disclosed peptide use last year — and 84% got their information from influencers, not doctors. The full survey data.
Industry7 min read
Novo Sues Lilly Over GLP-1 Ads: The Dose Mismatch
Novo asked a court to halt Lilly's GLP-1 ads for pitting max-dose tirzepatide against outdated semaglutide doses. What the trial data actually shows.
Industry8 min read
Are Peptides Legal in the US? What the FDA Vote Means
Most peptides aren't FDA-approved drugs — which isn't the same as illegal. The plain-English answer, and what the FDA's July vote did and didn't change.
Industry4 min read
Buy Peptides With Crypto: Vendors & Discounts
Card networks keep dropping peptide sellers, so crypto is now the default. Which vendors take Bitcoin, who adds a crypto discount, and how it works.
Industry6 min read
FDA Panel Backs 6 Peptides for Compounding, Rejects DSIP
FDA advisers backed 6 of 7 peptides for compounding — Semax and Epitalon included — and rejected DSIP, all over staff objections. Every vote tally.
Industry5 min read
Peptides for Long COVID: What the Trials Show
BPC-157, MOTS-c and microdosed GLP-1s are marketed for Long COVID while semaglutide and tirzepatide trials run. What's studied, what isn't.
Industry5 min read
GLP-1 Use Hits Record 11% as US Obesity Rate Falls
GLP-1 use hit a record 11% of US adults as obesity fell to 36.4% — Gallup's first decline. What the surge means for access, cost, and cheaper routes.
Industry5 min read
Orforglipron Beats Oral Semaglutide: ACHIEVE-3 Data
The first head-to-head of two GLP-1 pills is out: orforglipron beat oral semaglutide on blood sugar and weight — but at a steeper GI cost.
Industry7 min read
Medicare GLP-1 Bridge Live: Who Gets the $50 Copay
Medicare's GLP-1 Bridge went live July 1 with a $50 copay — but only ~3.8M qualify, retatrutide isn't covered, and the copay has a catch.
Industry7 min read
Bofanglutide: Biweekly GLP-1 Beats Semaglutide
A 272-patient phase 2b trial found biweekly bofanglutide cut HbA1c more than semaglutide. Here's what the every-2-week GLP-1 means for buyers.
Industry6 min read
Viking's VK3019: New Amylin Drug Enters Trials
Viking started Phase 1 of VK3019, an amylin-calcitonin drug for weight loss. What DACRA means and the amylin peptides you can buy now.
Industry6 min read
One Person Got Retatrutide Early. Here's the Catch
The FDA granted one 79-year-old compassionate-use access to retatrutide. Here's why there's no legal prescription route — and where buyers source it.
Industry6 min read
Quintuple Agonist Beats Retatrutide in Rats: VRX-0075
A 5-receptor obesity peptide, VRX-0075, beat retatrutide for weight loss in obese rats at ADA 2026. What the data means and what you can buy now.
Industry5 min read
Aleniglipron: The Next Oral GLP-1 Pill (And What to Buy Now)
Structure's aleniglipron hit ~16% weight loss as a once-daily pill at ADA 2026 — but it's years from pharmacy shelves. Here's what you can access today.
Industry4 min read
BELIEVE Trial: GLP-1 Combo Keeps 92% Fat Loss
Bimagrumab plus semaglutide hit 22.1% weight loss with 92.8% from fat in the BELIEVE trial. What it means for muscle-preserving peptide stacks.
Industry4 min read
GLP-1 Users Walk 560 Fewer Steps a Day: ENDO 2026
A Fitbit study at ENDO 2026 found GLP-1 users moved less after starting treatment. What it means for muscle, results, and how to push back.